Insider Transactions in Q2 2025 at Cytom X Therapeutics, Inc. (CTMX)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2025
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
13,884
-4.85%
|
$27,768
$2.69 P/Share
|
|
Jun 16
2025
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,614
-4.48%
|
$21,228
$2.69 P/Share
|
|
Jun 16
2025
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
55,511
-4.85%
|
$111,022
$2.69 P/Share
|
|
Jun 13
2025
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+11.59%
|
-
|
|
Jun 13
2025
|
Christopher Ogden Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+13.67%
|
-
|
|
Jun 13
2025
|
Christopher Ogden Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,641
-0.82%
|
$3,282
$2.95 P/Share
|
|
Jun 13
2025
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+11.58%
|
-
|